News|Articles|July 9, 2018

Takeda Opens New Global Headquarters

Author(s)Pharmaceutical Technology Editors

The company opened its new global headquarters in Japan.

Takeda Pharmaceutical announced the opening of its new headquarters in Nihonbashi, Tokyo on July 2, 2018. The building was completed in March 2018.

The company announced that it agreed to sell its previous Tokyo headquarters as well as its Shin-Edobashi building to Takashimaya Company in December 2017 for 49.5 yen (approximately US$447 million).

Source: Takeda Pharmaceutical

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

IoT Internet of Things, Internet network technology, digital software development, big data concept | Image Credit: ©tippapatt -stock.adobe.com

October 13th, 2026

Using Automation to Enhance Manufacturing: Building the Foundation for Pharma 4.0

This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.

October 12th, 2026

PharmTech AI Pulse Check: AI Watermark Vulnerability

PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.

October 9th, 2026

Q&A: Patient-Centric Drug Development Should Start at Product Definition

Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.

FDA approves oral antiviral pritelivir for drug-resistant herpes sores in immunocompromised patients.

October 9th, 2026

Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral

The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.

October 9th, 2026

PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights

This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.

FDA approves Weltruza, a once-monthly subcutaneous olanzapine that drops post-injection monitoring.

October 9th, 2026

What the Olanzapine Depot Approval Means for CMC Teams

FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com

October 9th, 2026

Power of Two One-Sided Tests with Unequal Variances

Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.

October 8th, 2026

Manufacturing Intelligence: Why NAMs May Not Impact Development Pipelines

Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.

Takeda Opens New Global Headquarters

Related to this article

Trending on Pharmaceutical Technology

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2

Complying with International Pharmacopoeias

Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral

What the Olanzapine Depot Approval Means for CMC Teams

Q&A: Patient-Centric Drug Development Should Start at Product Definition